10/10! I previously tried another service, but the pricing was baffling
Catalyst Events and Market Watch Significant upcoming catalyst events include the phase [name] readout of Eli Lillys glipron, which will indicate the efficacy of oral GLP-1s, followed by Pfizers glipron and other oral GLP-1s by 2028
Dual Agonists Under Investigation Tirzepatide (Mounjaro) was approved by the FDA on May 13, 2022 for the treatment of type 2 diabetes in adults, making it the first and only GIP/GLP-1 receptor agonist
Sanofi aims at making therapy outcomes more effective, while also expanding treatment accessibility through research and product development initiatives
Upcoming catalyst events the order and 6ming of expected GLP-1 and other clinical outcomes in weight loss/obesity to be announced
Semaglutide is available in three formulations: the injectable Ozempic, Wegovy, and the oral tablet Rybelsus